Methodology: how we compare
Updated: 2026-10-17
1. Where the data comes from
- Read by GLP Claro: we open the clinic’s public page and copy the price as shown, with the date.
- Third-party figure: when the clinic page could not be read (blocked, or price only inside the intake quiz) we use the figure published by a public tracker and label it, linking the source (e.g. AllGLP1 or GLP-1 Watchdog). These should be re-verified.
- Missing values stay empty. We never invent or estimate a price a clinic does not publish.
2. How we calculate
- All-in per month = published regular price + mandatory membership. If billed every 4 weeks we convert to monthly (× 13 ÷ 12).
- 6-month estimate = intro price (if any, for its duration) + regular price for the remaining months + membership. If price varies by dose we show a range between the lowest and highest published price. It is a calculation, not a quote or a dosing recommendation.
- “From” / “as low as” prices without a stated plan are shown separately with an asterisk and sorted last.
3. How we rank
By price only. (The Spanish edition defaults to showing Spanish-speaking clinics first, then price; that is a language filter, not a paid one.) No payment, commission or featured listing ever changes the order. Any future paid listing will appear in a separate box labeled “Sponsored”, outside the table.
4. Transparency signals
Not a safety or medical-quality rating. We check: (a) whether FDA posted a warning letter to the company in the telehealth GLP-1 batches we reviewed (Sep 2025, Feb–Mar 2026, Jun 2026: FDA, March 2026, June 2026 list); (b) whether we read the price directly; (c) published refund/cancellation policy; (d) published service states; (e) whether the clinic claims LegitScript certification (not independently verified; check LegitScript).
- Orange: FDA posted a letter to that company. It may have been corrected since; we link the letter.
- Green: no letter in the reviewed batches and at least 2 of signals (b)–(e).
- Yellow: no letter found but incomplete information.
5. Updates and corrections
Version 1: manual review with a date on every clinic. Goal: automated daily checks with human review of large changes. Found an error? Contact us (corrections email coming soon) and we will fix it with a change note.
See also: Affiliate disclosure.
Maximum 6-month difference ($1,500)
We group offers into comparable types: same drug, brand or compounded, same form (injectable or oral) and, for brand, the same product. We only count clinics without an FDA warning letter, and only prices GLP Claro read on the clinic's own page (never third-party figures). In each group with at least 2 options we subtract the lowest 6-month estimate from the highest. When an offer has a dose-based range we use its low end (the most conservative choice). Today the largest difference is $1,500 for compounded injectable tirzepatide (12 options): Willow $2,394 vs Lttl $894, using prices published as of 2026-10-17. It is recalculated automatically whenever we update the data. Excludes taxes, labs and special shipping.
FDA warning letters (10 clinics)
We review FDA warning letters published to GLP-1 telehealth companies (batches from Sep 2025, Feb–Mar 2026 and Jun 2026). If we find a letter addressed to the company, we flag it orange with date and link. A letter does not mean the issue persists today, and finding none guarantees nothing.
How we pick “Best in this comparison”
- We exclude options with an FDA warning letter and options without a published price.
- Among the rest, the best signal wins (green before yellow).
- On a tie, the lowest 6-month estimate wins; if still tied, the one with more trust signals.
In each comparison row we mark the best known value. Missing data shows “To be verified” and never wins. “Most trust signals” counts 5 signals: no FDA letter, price read by us, refund policy published, service states published, and LegitScript claimed or manufacturer program. “Most complete data” is the share of fields we know for that offer. If you compare brand with compounded, we warn you they are not equivalent. This compares published data; it is not medical advice.